The TNF-308 rs1800629 polymorphism is the one with the strongest evidence; it has been extensively studied in patients treated with biologic drugs, specifically etanercept, and diagnosed with autoimmune conditions such as psoriasis, rheumatoid arthritis, and Crohn’s disease, showing moderate evidence (level 2B). This evidence concerns the gene TNF and Crohn disease.